What is ABUS's P/E ratio?

ARBUTUS BIOPHARMA CORP (ABUS) currently trades at a P/E ratio of 5.06.

ARBUTUS BIOPHARMA CORP reports a Return on Equity (ROE) of 61.77%.

What is ABUS's dividend yield?

ARBUTUS BIOPHARMA CORP offers a dividend yield of 0.00%.

What is ABUS's Quality Score?

Our AI rates ABUS's overall financial quality at 69 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy ABUS?

Our AI Timing Score for ABUS is 56 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does ABUS belong to?

ARBUTUS BIOPHARMA CORP is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange

ABUS (NASDAQ) Stock Analysis | ARBUTUS BIOPHARMA CORP

Stock Check Daily update data at 8:30 AM
(Price: 2026-07-31 | FS: 2026-03-31)

ABUS AI Analysis Summary

Our AI summary for ABUS: ARBUTUS BIOPHARMA CORP (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 5.06, ROE of 61.77%, a dividend yield of 0.00%. Its financial Quality Score stands at 69/100 — mid-range fundamentals relative to the market. The AI Timing Score is 56/100 — technical signals are mixed; watch for a clearer trend. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

ABUS

ARBUTUS BIOPHARMA CORP

US:NASDAQ STOCK Healthcare >> Biotechnology

USD 4.34

-0.07 (-1.59%) Day Change

Watchlist Portfolio Compare Chart

5.06

P/E

0.00

D/E

61.8%

ROE

58.0%

ROA

0.00%

Div Yield

ARBUTUS BIOPHARMA CORP
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 4.34 Price -0.07 (-1.59%) Day Change	NEWS SCORE: N/A

ABUS, the overall quality is ok ( Quality = 69) and the timing to buy is ...(Sign In to See)...

Loading chart...

69 QUALITY

Signal: NEUTRAL

Signal Description: Company financial health is OK

Reason: Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
Acceleration of ROA growth rate is below our criteria.
Historical net profit margin is relatively low.

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not quite good , financial health is not good , and ability to make profit is ok , ...

Quality Factors

50%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	N/A
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	4.34
PBV / Sector	3.35 / 5.20
Earning Per Share	0.80

PE / Sector	5.06 / 19.97 GREAT
PEG or PE/Growth / Sector	N/A / 1.22
Average 1M Daily Value	9.34 M
Average 1W Daily Value	4.91 M GREAT

Timing Factors

28%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

41%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

68%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	83.95 / 98.71 GREAT
NPM Average (%) / Sector	-373.31 / -1,721.76
NPM Change Average (%) / Sector	23.36 / 5,211.62 GREAT
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	57.99 / 27.02 GREAT
ROA Average (%) / Sector	-23.30 / -368.17
ROA Change Average (%) / Sector	-62.48 / 5,404.12
ROE (%) / Sector	61.77 / 3.47 GREAT
ROE Average (%) / Sector	-34.65 / 6.51
ROE Change Average (%) / Sector	-60.10 / 2,128.13
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -1.75

Registration Details

Analyze Date	2026-08-01 07:59:25
Symbol	ABUS
Name	ARBUTUS BIOPHARMA CORP
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	197.54 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	871.14 / 9,903.94

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 701 Veterans Circle, Warminster, PA, United States, 18974

Phone: 267 469 0914

Website: https://www.arbutusbio.com

Sector: Healthcare >> Biotechnology

Description: Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.